Shares of Corvus Pharmaceuticals Inc (NASDAQ:CRVS) traded up 10.7% during mid-day trading on Thursday . The company traded as high as $4.75 and last traded at $4.56, 19,518 shares traded hands during trading. A decline of 85% from the average session volume of 133,489 shares. The stock had previously closed at $4.12.
Several equities research analysts recently commented on the stock. Mizuho restated a “buy” rating and issued a $7.00 price target on shares of Corvus Pharmaceuticals in a research report on Tuesday, October 29th. Zacks Investment Research upgraded shares of Corvus Pharmaceuticals from a “hold” rating to a “buy” rating and set a $3.75 price objective on the stock in a research report on Friday, November 1st. One research analyst has rated the stock with a hold rating and four have assigned a buy rating to the stock. Corvus Pharmaceuticals presently has a consensus rating of “Buy” and an average price target of $6.94.
The company has a current ratio of 9.23, a quick ratio of 9.23 and a debt-to-equity ratio of 0.03. The business has a fifty day moving average price of $3.31 and a two-hundred day moving average price of $3.79.
Corvus Pharmaceuticals (NASDAQ:CRVS) last posted its quarterly earnings results on Tuesday, October 29th. The company reported ($0.37) earnings per share for the quarter, beating the consensus estimate of ($0.42) by $0.05. As a group, analysts expect that Corvus Pharmaceuticals Inc will post -1.53 EPS for the current fiscal year.
Large investors have recently added to or reduced their stakes in the business. Parametric Portfolio Associates LLC acquired a new position in shares of Corvus Pharmaceuticals in the 2nd quarter valued at about $50,000. Paloma Partners Management Co purchased a new position in Corvus Pharmaceuticals during the second quarter valued at approximately $149,000. Jacobs Levy Equity Management Inc. acquired a new position in Corvus Pharmaceuticals in the 2nd quarter valued at approximately $223,000. Connor Clark & Lunn Investment Management Ltd. increased its stake in Corvus Pharmaceuticals by 9.1% in the 2nd quarter. Connor Clark & Lunn Investment Management Ltd. now owns 64,325 shares of the company’s stock valued at $241,000 after buying an additional 5,374 shares during the period. Finally, Fosun International Ltd increased its stake in Corvus Pharmaceuticals by 7.7% in the 2nd quarter. Fosun International Ltd now owns 184,116 shares of the company’s stock valued at $624,000 after buying an additional 13,142 shares during the period. 79.82% of the stock is currently owned by institutional investors.
About Corvus Pharmaceuticals (NASDAQ:CRVS)
Corvus Pharmaceuticals, Inc, a clinical stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology therapies. Its lead product candidate is CPI-444, an oral, small molecule antagonist of the A2A receptor that is in Phase I/Ib clinical trial for adenosine, an immune checkpoint.
Read More: Most Active Stocks
Receive News & Ratings for Corvus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Corvus Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.